<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728217</url>
  </required_header>
  <id_info>
    <org_study_id>RELOQ</org_study_id>
    <nct_id>NCT04728217</nct_id>
  </id_info>
  <brief_title>Health Related Quality of Life of Youth and Young Adults With Haemophilia A</brief_title>
  <acronym>RELOQ</acronym>
  <official_title>Health Related Quality of Life of Youth and Young Adults With Haemophilia A Treated With Efmoroctocog Alfa in Russia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The League of Clinical Research, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The League of Clinical Research, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research question:&#xD;
&#xD;
      Whether there are the changes in quality of life in patients with haemophilia A after&#xD;
      switching from SHL FVIII prophylaxis to efmoroctocog alfa prophylaxis?&#xD;
&#xD;
      A 12-month prospective open-label, single-arm multicentre study. Evaluation of parameters&#xD;
      will be carried out on the backdrop of patient treatment in the settings of routine medical&#xD;
      practice. No medical examinations/ procedures/ treatment(s) on the top of regular medical&#xD;
      practice are planned, except fixed time of examinations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Quality of life is among the key factors when medical decision about management of&#xD;
      haemophilia is taken. There are no scientific data on the HRQoL in patients after switching&#xD;
      from Standard Half Life (SHL) FVIII prophylaxis to efmoroctocog alfa (Extended Half Life,&#xD;
      EHL) prophylaxis in Russia.&#xD;
&#xD;
      It will be a 12-month prospective open-label, single-arm multicentre study. Evaluation of&#xD;
      parameters will be carried out on the backdrop of patient treatment in the settings of&#xD;
      routine medical practice. No medical examinations/ procedures/ treatment(s) on the top of&#xD;
      regular medical practice are planned, except fixed time of examinations. Providing the&#xD;
      centers/ patients with the study drug (efmoroctocog alfa) may be considered as interventional&#xD;
      component, whereas all administrations should be in accordance with Instruction on Medical&#xD;
      Use approved by Russian Ministry of Health.&#xD;
&#xD;
      Research question:&#xD;
&#xD;
      Whether there are the changes in quality of life in patients with haemophilia A after&#xD;
      switching from SHL FVIII prophylaxis to efmoroctocog alfa prophylaxis?&#xD;
&#xD;
      No hypothesis is formulated for this exploratory study. The obtained data will be used to&#xD;
      assess real world data on quality of life and clinical outcomes in patients with haemophilia&#xD;
      A after switching from SHL FVIII prophylaxis to efmoroctocog alfa prophylaxis in routine&#xD;
      medical practice in Russia&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A 12-month prospective open-label, single-arm multicentre study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Month 12</time_frame>
    <description>Haemophilia Adult Quality of Life Questionnaire (Haem-A-QoL) - for patients of 18-25 y.o.; total score, domain scores.&#xD;
or Haemophilia-specific Quality of Life assessment for children and adolescents Short Form (Haemo-QoL SF) - for patients 12-17 y.o.; total score, domain scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spontaneous bleedings</measure>
    <time_frame>Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Number from previous visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous bleedings - localisation</measure>
    <time_frame>Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Localisation of spontaneous bleedings: joints, muscles, subcutaneous/ submucosal, abdominal/ gastrointestinal, retroperitoneal, genitourinary, CNS, pharyngeal, other.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-traumatic bleedings</measure>
    <time_frame>Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Number from previous visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-traumatic bleedings - localisation</measure>
    <time_frame>Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Localisation of post-traumatic bleedings: joints, muscles, subcutaneous/ submucosal, abdominal/ gastrointestinal, retroperitoneal, genitourinary, CNS, pharyngeal, other.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration of efmorococtog alfa for correction of bleedings</measure>
    <time_frame>Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Dose of efmorococtog alfa: IU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery/ Invasive Procedures: major</measure>
    <time_frame>Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Number from previous visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery/ Invasive Procedures: minor</measure>
    <time_frame>Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Number from previous visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration of efmorococtog alfa for correction of bleedings for Surgery/ Invasive Procedures</measure>
    <time_frame>Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Dose of efmorococtog alfa: IU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisations</measure>
    <time_frame>Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Number from previous visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisations: duration</measure>
    <time_frame>Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Total duration of all hospitalisations: days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemophilia Joint Health Score</measure>
    <time_frame>Day 0 - Month 6 - Month 12</time_frame>
    <description>Hemophilia Joint Health Score 2.1 for knee, elbow, ankle (left, right): score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Joints</measure>
    <time_frame>Day 0 - Month 6 - Month 12</time_frame>
    <description>Target joints: knee, elbow, ankle, hip, shoulder, carpal, other (left, right): yes/ no.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound Scoring</measure>
    <time_frame>Day 0 - Month 6 - Month 12</time_frame>
    <description>Ultrasound scoring (HEAD-US): score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factor VIII Activity</measure>
    <time_frame>Day 0 - Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Factor VIII Activity (before injection; 30 min after injection), clotting assays (one stage): IU/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factor VIII Inhibitor Activity</measure>
    <time_frame>Day 0 - Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Factor VIII Inhibitor Activity: Nijmegen-Bethesda unit/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration of efmoroctocog alfa</measure>
    <time_frame>Day 0 - Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Administration of efmoroctocog alfa, frequency: no. of injections per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration of efmoroctocog alfa: factor consumption</measure>
    <time_frame>Day 0 - Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Administration of efmoroctocog alfa, factor consumption: IU per week, IU/kg per week (calculation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Previous treatment/ prophylaxis of haemophilia</measure>
    <time_frame>Day 0 - Month 1 - Month 3 - Month 6 - Month 12</time_frame>
    <description>Generic drug name.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Patients receiving Efmoroctocog alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For long term prophylaxis, the recommended starting dose is 50 IU of factor VIII per kg body weight at intervals of 3 to 5 days. The dose may be adjusted based on patient response in the range of 25 to 65 IU/kg. In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efmoroctocog Alfa Injection [Eloctate]</intervention_name>
    <description>Efmoroctocog alfa should be administered according to Summary of Product Characteristics (SmPC)/ Instruction on Medical Use approved by Russian Ministry of Health ЛП-006034 (13.01.2020).</description>
    <arm_group_label>Patients receiving Efmoroctocog alfa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed consent form.&#xD;
&#xD;
          2. Adults, adolescents and children (12-25 years old) with haemophilia A with ABR ≥ 2 on&#xD;
             at least one-year SHL FVIII prophylaxis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have had hypersensitivity reactions to efmoroctocog alfa or other&#xD;
             constituents of the product.&#xD;
&#xD;
          2. History of Factor VIII inhibitors.&#xD;
&#xD;
          3. Patients who have other haemostatic disorders.&#xD;
&#xD;
          4. Patients participating in interventional studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oleg Melikhov, MD</last_name>
    <phone>0079166950530</phone>
    <email>melikhov.oleg@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Svetlana Elkonina</last_name>
    <phone>0079164454877</phone>
    <email>elkonina.svetlana@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>League of Clinical Research (LeagueCRR)</name>
      <address>
        <city>Moscow</city>
        <zip>119590</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleg G Melikhov, MD, PhD</last_name>
      <phone>0079166950530</phone>
      <email>melikhov.oleg@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Svetlana I Elkonina, MD</last_name>
      <phone>0079164454877</phone>
      <email>elkonina.svetlana@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilia A</keyword>
  <keyword>Health-related Quality of Life</keyword>
  <keyword>Efmoroctocog alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
    <mesh_term>Immunoglobulin Fc Fragments</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

